A Prospective Double-Blind Study of Retrovir in Early HIV Infection
To evaluate the safety and tolerance of chronic administration of Retrovir (AZT) to adult patients with early manifestations of HIV disease. To assess the efficacy of AZT therapy in the treatment of HIV disease in these patients.
(12/01/89) Information supplied by drug company update. Study discontinued due to positive data from ACTG 016.
|Study Design:||Masking: Double-Blind
Primary Purpose: Treatment
|Official Title:||A Prospective Double-Blind Study of Retrovir in Early HIV Infection|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00002045
|United States, North Carolina|
|Glaxo Wellcome Inc|
|Research Triangle Park, North Carolina, United States, 27709|